Covington advised Bristol Myers Squibb on the transaction, while Cooley and Wilson Sonsini Goodrich & Rosati advised RayzeBio Inc. Goodwin advised Centerview Partners in its role...
Bristol Myers Squibb’s $4.1 Billion Acquisition of RayzeBio
Radionetics Oncology’s $52.5 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Radionetics Oncology on IP matters related to the transaction. Radionetics Oncology announced that it has raised $52.5 million in Series...
Sudo Biosciences’s $116 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Sudo on intellectual property matters related to the transaction. Sudo Biosciences (“Sudo”) announced the close of a $116 million Series B...
Melinta Therapeutics’ Licensing Agreement with Venatorx Pharmaceuticals
Wilson Sonsini Goodrich & Rosati advised Venatorx on IP matters in the transaction. Melinta Therapeutics LLC (Melinta) and Venatorx Pharmaceuticals, Inc. (Venatorx), announced that they have...
LENZ Therapeutics’ Merger with Graphite Bio
Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction, Goodwin Procter is representing Graphite Bio and Latham & Watkins is representing the placements...
Insilico Medicine’s $80 Million Agreement with Exelixis
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
CG Oncology’s $105 Million Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresite Capital on the transaction. CG Oncology, Inc. announced the close of an oversubscribed $105 million crossover financing round, co-led...
Upstream Bio’s $200 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Venrock Healthcare Capital Partners on IP matters related to the transaction. Upstream Bio, a clinical-stage biotech company, announced the completion of...
Boundless Bio’s $100 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Boundless Bio on IP matters related to the transaction. Boundless Bio, a clinical-stage, next-generation precision oncology company developing innovative therapeutics...
Gilead’s Acquisition of XinThera
Wilson Sonsini Goodrich & Rosati advised XinThera on the transaction. Gilead Sciences announced the acquisition of San Diego-based XinThera, a privately held biotech company. The acquisition...
LENZ Therapeutics’ $83.5 Million Series B Financing
Wilson Sonsini Goodrich & Rosati represented LENZ in the transaction. Biopharmaceutical company LENZ Therapeutics announced that it raised $83.5 million in an oversubscribed Series B financing....
Metagenomi’s $100 Million Series B Extension Financing
Wilson Sonsini Goodrich & Rosati advised Novo Holdings and Metagenomi on the deal. Fenwick represented Metagenomi. Gene editing company Metagenomi announced a $100 million Series B...